<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250109011455&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250109011455&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 09 Jan 2025 06:14:56 +0000</lastbuilddate>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e9. doi: 10.1016/j.jacc.2024.10.116.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779064</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.116>10.1016/j.jacc.2024.10.116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779064</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Suvasini Lakshmanan</dc:creator>
<dc:creator>Venkat Sanjay Manubolu</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</dc:title>
<dc:identifier>pmid:39779064</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.116</dc:identifier>
</item>
<item>
<title>How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779063/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e7. doi: 10.1016/j.jacc.2024.08.088.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779063/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779063</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.088>10.1016/j.jacc.2024.08.088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779063</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gianluca Iacobellis</dc:creator>
<dc:creator>Alexis Elias Malavazos</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</dc:title>
<dc:identifier>pmid:39779063</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.088</dc:identifier>
</item>
<item>
<title>Reply: Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e17. doi: 10.1016/j.jacc.2024.10.115.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779062</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.115>10.1016/j.jacc.2024.10.115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779062</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sahmin Lee</dc:creator>
<dc:creator>Jae-Kwan Song</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</dc:title>
<dc:identifier>pmid:39779062</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.115</dc:identifier>
</item>
<item>
<title>Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779061/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e15. doi: 10.1016/j.jacc.2024.09.1243.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779061/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779061</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1243>10.1016/j.jacc.2024.09.1243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779061</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jonathan L Ciofani</dc:creator>
<dc:creator>Ravinay Bhindi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</dc:title>
<dc:identifier>pmid:39779061</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1243</dc:identifier>
</item>
<item>
<title>Reply: Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e13. doi: 10.1016/j.jacc.2024.09.1242.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779060</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1242>10.1016/j.jacc.2024.09.1242</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779060</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rodney H Falk</dc:creator>
<dc:creator>Sarah A M Cuddy</dc:creator>
<dc:creator>Osnat Itzhaki Ben Zadok</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</dc:title>
<dc:identifier>pmid:39779060</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1242</dc:identifier>
</item>
<item>
<title>Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e11-e12. doi: 10.1016/j.jacc.2024.08.087.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779059</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.087>10.1016/j.jacc.2024.08.087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779059</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Giuseppe Vergaro</dc:creator>
<dc:creator>Giorgia Panichella</dc:creator>
<dc:creator>Vincenzo Castiglione</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</dc:title>
<dc:identifier>pmid:39779059</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.087</dc:identifier>
</item>
<item>
<title>Introducing Brief Features in JACC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779058/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):86-87. doi: 10.1016/j.jacc.2024.12.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779058/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779058</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.001>10.1016/j.jacc.2024.12.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779058</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Introducing Brief Features in JACC</dc:title>
<dc:identifier>pmid:39779058</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.001</dc:identifier>
</item>
<item>
<title>Prostanoids and Heart Failure: Friend or Foe?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):71-73. doi: 10.1016/j.jacc.2024.11.016.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779057</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.016>10.1016/j.jacc.2024.11.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779057</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prostanoids and Heart Failure: Friend or Foe?</dc:title>
<dc:identifier>pmid:39779057</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.016</dc:identifier>
</item>
<item>
<title>Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779056/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Systemic thromboxane A(2) generation as measured by urinary TXB(2)-M(GFR) was significantly associated with HF risk and remained so after accounting for traditional risk factors. Urinary TXB(2)-M(GFR) is therefore a potentially useful novel biomarker to identify at-risk individuals who might benefit from aggressive primary prevention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):58-70. doi: 10.1016/j.jacc.2024.09.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Systemic thromboxane A<sub>2</sub> generation, which is readily assessed by quantifying thromboxane B<sub>2</sub> metabolites (TXB<sub>2</sub>-M) in the urine, is associated with impaired cardiac performance and mortality in aspirin (ASA) users with heart failure (HF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine the association of urinary TXB<sub>2</sub>-M with the risk of developing HF in individuals without prior history of HF and with normal left ventricular function irrespective of ASA use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Urine TXB<sub>2</sub>-M were measured by immunoassay and adjusted to urine concentration and renal function (TXB<sub>2</sub>-M<sub>GFR</sub>) in 2,611 Framingham Heart Study participants (54.9% women, mean age 65 ± 9 years, 43.8% ASA users) without prior history of HF and with left ventricular ejection fraction (LVEF) ≥55%. The association of TXB<sub>2</sub>-M<sub>GFR</sub> with HF risk over a median observation period of 14.8 years (Q1-Q3: 12.6-15.7 years) was modeled using Cox regression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: HF occurred in 189 participants (7.2%), with 104 of the first events (55.0%) classified as HF with preserved LVEF, 56 (29.6%) as HF with reduced LVEF, and 29 (15.3%) were unclassifiable. TXB<sub>2</sub>-M<sub>GFR</sub> levels, above compared to below, of 16.6 and 62.1 filtered prostanoid units for ASA users and nonusers, respectively, were associated with increased risk of developing HF (HR: 1.81; 95% CI: 1.38-2.64; P &lt; 0.0001, adjusted for age, sex, ASA use, and HF risk factors), including both HF subtypes (HF with preserved LVEF: HR: 1.81; 95% CI: 1.17-2.80; P = 0.0081, and HF with reduced LVEF: HR: 2.63; 95% CI: 1.48-4.68; P = 0.0010, adjusted for age, sex, ASA use, and cardiovascular disease). Neither ASA use nor evidence of platelet activation, as measured by plasma P-selectin, were independently associated with HF risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Systemic thromboxane A<sub>2</sub> generation as measured by urinary TXB<sub>2</sub>-M<sub>GFR</sub> was significantly associated with HF risk and remained so after accounting for traditional risk factors. Urinary TXB<sub>2</sub>-M<sub>GFR</sub> is therefore a potentially useful novel biomarker to identify at-risk individuals who might benefit from aggressive primary prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779056/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779056</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.010>10.1016/j.jacc.2024.09.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779056</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jeffrey J Rade</dc:creator>
<dc:creator>Shari S Kronsberg</dc:creator>
<dc:creator>Thomas S Kickler</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Vanessa Xanthakis</dc:creator>
<dc:creator>Matthew G Nayor</dc:creator>
<dc:creator>Bruce A Barton</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure</dc:title>
<dc:identifier>pmid:39779056</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.010</dc:identifier>
</item>
<item>
<title>Complete Revascularization Wins in ST-Segment Elevation Myocardial Infarction, But Timing Remains Flexible</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779055/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):39-41. doi: 10.1016/j.jacc.2024.10.078.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779055/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779055</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.078>10.1016/j.jacc.2024.10.078</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779055</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Ehtisham Mahmud</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Complete Revascularization Wins in ST-Segment Elevation Myocardial Infarction, But Timing Remains Flexible</dc:title>
<dc:identifier>pmid:39779055</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.078</dc:identifier>
</item>
<item>
<title>Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with STEMI and multivessel disease, outcomes were better with immediate or staged CR compared with culprit vessel-only treatment, whether with angiographic or functional guidance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):19-38. doi: 10.1016/j.jacc.2024.09.1231.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, most but not all randomized trials have reported that complete revascularization (CR) offers advantages over culprit vessel-only revascularization. In addition, the optimal timing and assessment methods for CR remain undetermined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to identify the optimal revascularization strategy in patients with STEMI and multivessel disease, using a network meta-analysis of randomized controlled trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We searched PUBMED and EMBASE for randomized trials evaluating revascularization strategies in patients with STEMI and multivessel disease through July 2024. A network meta-analysis was performed analyzing CR vs culprit vessel-only revascularization as well as the timing of CR (immediate CR vs staged CR). Outcomes were also assessed with 4 CR strategies based on whether revascularization was immediate or staged and whether it was angiographically guided or functionally guided. The primary outcome was major adverse cardiovascular events (MACE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 26 randomized trials that enrolled 15,902 patients were included. The mean weighted duration of follow-up was 25.2 ± 15.7 months. MACE was reduced with both immediate CR and staged CR compared with culprit-vessel-only treatment (RR: 0.48; 95% CI: 0.36-0.64 and RR: 0.65; 95% CI: 0.52-0.82, respectively), whether with angiographic or functional guidance. Immediate CR was associated with reduced MACE compared with staged CR (RR: 0.74; 95% CI: 0.56-0.97), whether CR was guided angiographically or functionally (RR: 0.77; 95% CI: 0.61-0.99 and RR: 0.49; 95% CI: 0.27-0.89, respectively) caused by reductions in MI. However, when the analysis was restricted to studies that reported both all MI and nonprocedural MI, the benefit of immediate CR in reducing MI compared with staged CR was diminished after excluding procedural MI (RR: 0.44; 95% CI: 0.27-0.71 with procedural MI vs RR: 0.65; 95% CI: 0.36-1.16 without procedural MI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with STEMI and multivessel disease, outcomes were better with immediate or staged CR compared with culprit vessel-only treatment, whether with angiographic or functional guidance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39779054</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1231>10.1016/j.jacc.2024.09.1231</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779054</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Keitaro Akita</dc:creator>
<dc:creator>Yuko Kiyohara</dc:creator>
<dc:creator>Hisato Takagi</dc:creator>
<dc:creator>Alexandros Briasoulis</dc:creator>
<dc:creator>Jose Wiley</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis</dc:title>
<dc:identifier>pmid:39779054</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1231</dc:identifier>
</item>
<item>
<title>Deep learning for cardiac abnormalities in chest X-rays: performance metrics with imbalanced data and extracardiac objects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae759. doi: 10.1093/eurheartj/ehae759. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39776179</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae759>10.1093/eurheartj/ehae759</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776179</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Eisuke Kagawa</dc:creator>
<dc:creator>Masaya Kato</dc:creator>
<dc:creator>Keigo Dote</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning for cardiac abnormalities in chest X-rays: performance metrics with imbalanced data and extracardiac objects</dc:title>
<dc:identifier>pmid:39776179</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae759</dc:identifier>
</item>
<item>
<title>Giant left atrial appendage aneurysm: a source of multiple thrombotic events despite medical therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae935. doi: 10.1093/eurheartj/ehae935. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39776175</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae935>10.1093/eurheartj/ehae935</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776175</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacopo Lin</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Michele De Bonis</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Giant left atrial appendage aneurysm: a source of multiple thrombotic events despite medical therapy</dc:title>
<dc:identifier>pmid:39776175</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae935</dc:identifier>
</item>
<item>
<title>Coffee drinking timing and mortality in US adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae871. doi: 10.1093/eurheartj/ehae871. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To identify the patterns of coffee drinking timing in the US population and evaluate their associations with all-cause and cause-specific mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study included 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018 who had complete information on dietary data and 1463 adults from the Women's and Men's Lifestyle Validation Study who had complete data on 7-day dietary record. Clustering analysis was used to identify patterns of coffee drinking timing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this observational study, two distinct patterns of coffee drinking timing [morning type (36% of participants) and all-day-type patterns (14% of participants)] were identified in the National Health and Nutrition Examination Survey and were validated in the Women's and Men's Lifestyle Validation Study. During a median (interquartile range) follow-up of 9.8 (9.1) years, a total of 4295 all-cause deaths, 1268 cardiovascular disease deaths, and 934 cancer deaths were recorded. After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders, the morning-type pattern, rather than the all-day-type pattern, was significantly associated with lower risks of all-cause (hazard ratio: .84; 95% confidential interval: .74-.95) and cardiovascular disease-specific (hazard ratio: .69; 95% confidential interval: .55-.87) mortality as compared with non-coffee drinking. Coffee drinking timing significantly modified the association between coffee intake amounts and all-cause mortality (P-interaction = .031); higher coffee intake amounts were significantly associated with a lower risk of all-cause mortality in participants with morning-type pattern but not in those with all-day-type pattern.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39776171</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae871>10.1093/eurheartj/ehae871</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776171</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xuan Wang</dc:creator>
<dc:creator>Hao Ma</dc:creator>
<dc:creator>Qi Sun</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Yoriko Heianza</dc:creator>
<dc:creator>Rob M Van Dam</dc:creator>
<dc:creator>Frank B Hu</dc:creator>
<dc:creator>Eric Rimm</dc:creator>
<dc:creator>JoAnn E Manson</dc:creator>
<dc:creator>Lu Qi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coffee drinking timing and mortality in US adults</dc:title>
<dc:identifier>pmid:39776171</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae871</dc:identifier>
</item>
<item>
<title>Start your day with a morning coffee!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae823. doi: 10.1093/eurheartj/ehae823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39776142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae823>10.1093/eurheartj/ehae823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776142</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Start your day with a morning coffee!</dc:title>
<dc:identifier>pmid:39776142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae823</dc:identifier>
</item>
<item>
<title>Efficacy of aggressive lipid-lowering therapy on plaque stabilization in femoropopliteal disease, assessed using near-infrared spectroscopy intravascular ultrasound</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776140/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae900. doi: 10.1093/eurheartj/ehae900. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776140/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39776140</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae900>10.1093/eurheartj/ehae900</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776140</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yusuke Sato</dc:creator>
<dc:creator>Tetsuji Morishita</dc:creator>
<dc:creator>Hiroshi Tada</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Efficacy of aggressive lipid-lowering therapy on plaque stabilization in femoropopliteal disease, assessed using near-infrared spectroscopy intravascular ultrasound</dc:title>
<dc:identifier>pmid:39776140</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae900</dc:identifier>
</item>
<item>
<title>Combustible cigarette smoking harms nearly every organ in the body</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae896. doi: 10.1093/eurheartj/ehae896. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39775792</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae896>10.1093/eurheartj/ehae896</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775792</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Danbee Kang</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Combustible cigarette smoking harms nearly every organ in the body</dc:title>
<dc:identifier>pmid:39775792</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae896</dc:identifier>
</item>
<item>
<title>Novel technology, novel challenges: How do we compare the performance of artificial intelligence to human experts?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae760. doi: 10.1093/eurheartj/ehae760. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39775785</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae760>10.1093/eurheartj/ehae760</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775785</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Pierre Elias</dc:creator>
<dc:creator>Shreyas Bhave</dc:creator>
<dc:creator>Timothy Joseph Poterucha</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Novel technology, novel challenges: How do we compare the performance of artificial intelligence to human experts?</dc:title>
<dc:identifier>pmid:39775785</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae760</dc:identifier>
</item>
<item>
<title>Genius and the CVD Polypill-A Step Toward Achieving Health Equity?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4820. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39775777</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4820>10.1001/jamacardio.2024.4820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775777</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Genius and the CVD Polypill-A Step Toward Achieving Health Equity?</dc:title>
<dc:identifier>pmid:39775777</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4820</dc:identifier>
</item>
<item>
<title>Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this economic evaluation suggest that polypill treatment could be a high value intervention for a low-income, majority Black population with limited access to health care services. It could additionally reduce health disparities.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4812. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Southern Community Cohort Study (SCCS) Polypill Trial showed that a cardiovascular polypill (a single pill containing a statin and 3 half-standard dose antihypertensive medications) effectively controls cardiovascular disease (CVD) risk factors in a majority Black race and low-income population. The cost-effectiveness of polypill treatment in this population has not been previously studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the cost-effectiveness of the cardiovascular polypill.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A discrete-event simulation version of the well-established CVD policy model simulated clinical and economic outcomes of the SCCS Polypill Trial from a health care sector perspective. A time horizon of 10 years was adopted. Polypill treatment was priced at $463 per year in the base-case analysis. Model input data were derived from the National Health and Nutrition Examination Survey, Medical Expenditure Panel Survey, pooled longitudinal cohort studies, the SCCS Polypill Trial, and published literature. Two cohorts were analyzed: an SCCS Polypill Trial-representative cohort of 100 000 individuals and all trial-eligible non-Hispanic Black US adults. Study parameters and model inputs were varied extensively in 1-way and probabilistic sensitivity analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Polypill treatment or usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: Primary outcomes were direct health care costs (US dollar 2023) and quality-adjusted life-years (QALYs), both discounted 3% annually, and the incremental cost per QALY gained.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the trial-representative cohort of 100 000 individuals (mean [SD] age, 56.9 [5.9] years; 61 807 female [61.8%]), polypill treatment was projected to yield a mean of 1190 (95% uncertainty interval, 287-2159) additional QALYs compared with usual care, at a cost of approximately $10 152 000. Hence, polypill treatment was estimated to cost $8560 per QALY gained compared with usual care and was high value (&lt;$50 000 per QALY gained) in 99% of simulations. Polypill treatment was estimated to be high value when priced at $559 or less per year and cost saving when priced at $443 or less per year. In almost all sensitivity analyses, polypill treatment remained high value. In a secondary analysis of 3 602 427 trial-eligible non-Hispanic Black US adults (mean [SD] age, 55.4 [7.6] years; 2 006 597 female [55.7%]), polypill treatment was high value, with an estimated cost of $13 400 per QALY gained.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this economic evaluation suggest that polypill treatment could be a high value intervention for a low-income, majority Black population with limited access to health care services. It could additionally reduce health disparities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39775718</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4812>10.1001/jamacardio.2024.4812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775718</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ciaran N Kohli-Lynch</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Kirsten Bibbins-Domingo</dc:creator>
<dc:creator>Neil Jordan</dc:creator>
<dc:creator>Dustin French</dc:creator>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Thomas J Wang</dc:creator>
<dc:creator>Brandon K Bellows</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population</dc:title>
<dc:identifier>pmid:39775718</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4812</dc:identifier>
</item>
<item>
<title>Recurrent Chest Pain in a Young Female Patient With Family History of Cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774791/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109011455&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774791/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109011455&v=2.18.0.post9+e462414">39774791</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4823>10.1001/jamacardio.2024.4823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774791</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ushasi Saraswati</dc:creator>
<dc:creator>Jaideep Singh Bhalla</dc:creator>
<dc:creator>Allan L Klein</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Recurrent Chest Pain in a Young Female Patient With Family History of Cancer</dc:title>
<dc:identifier>pmid:39774791</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4823</dc:identifier>
</item>





























</channel>
</rss>